{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:16:14Z","timestamp":1761174974300,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cmi.2023.02.020","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T02:14:52Z","timestamp":1677809692000},"page":"673-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia"],"prefix":"10.1016","volume":"29","author":[{"given":"Ryan C.","family":"Maves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre C.","family":"Kalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.02.020_bib1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.02.020_bib2","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.26.2100704","article-title":"A\u00a0point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from combatting bacterial resistance in Europe CDI (COMBACTE-CDI)","volume":"27","author":"Viprey","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2023.02.020_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2021.1900995","article-title":"Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment","volume":"13","author":"Kang","year":"2021","journal-title":"Gut Microbe"},{"key":"10.1016\/j.cmi.2023.02.020_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2012.11.014","article-title":"Ecological impact of doxycycline at low dose on normal oropharyngeal and intestinal microflora","volume":"41","author":"Rashid","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2023.02.020_bib5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1017\/ice.2015.220","article-title":"A\u00a0comprehensive assessment across the healthcare continuum: risk of hospital-associated Clostridium difficile infection due to outpatient and inpatient antibiotic exposure","volume":"36","author":"Tartof","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2023.02.020_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajic.2013.08.009","article-title":"Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder","volume":"42","author":"Ramanathan","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2023.02.020_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/cix833","article-title":"Low risk of primary clostridium difficile infection with tetracyclines: a systematic review and metaanalysis","volume":"66","author":"Tariq","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.02.020_bib8","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections--full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.02.020_bib9","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.02.020_bib10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.02.020_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.cmi.2022.07.022","article-title":"Ceftriaxone versus ampicillin for the treatment of community-acquired pneumonia. A propensity matched cohort study","volume":"29","author":"Guz","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.02.020_bib12","first-page":"45","article-title":"Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia","volume":"73","author":"Chalmers","year":"2016","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2023.02.020_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00417-21","article-title":"Characterizing risk factors for Clostridioides difficile infection among hospitalized patients with community-acquired pneumonia","volume":"65","author":"Rhodes","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.02.020_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.20411\/pai.v7i1.512","article-title":"Why does doxycycline pose a relatively low risk for promotion of Clostridioides difficile infection?","volume":"7","author":"Xu","year":"2022","journal-title":"Pathog Immun"},{"key":"10.1016\/j.cmi.2023.02.020_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/cid\/cis457","article-title":"Does doxycycline protect against development of Clostridium difficile infection?","volume":"55","author":"Doernberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.02.020_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jhm.8","article-title":"Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia","volume":"1","author":"Flanders","year":"2006","journal-title":"J\u00a0Hosp Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:49Z","timestamp":1761118429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1198743X23000903"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.02.020","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? Doxycycline in combination with ceftriaxone for the treatment of community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}